In contrast, auranofin (AUR), an inhibitor of the antioxidant thioredoxin reductase shows a strong anti-MM activity, synergises with BTZ, and alleviates BTZ intrinsec insensitivity as well as cell tumour microenvironment (TME)-mediated cell resistance. Here, CASC3 is linked to Miyoshi myopathy.